HTRA inhibitors
Novel Ahp-cyclodepsipeptide-based HTRA inhibitors for the treatment of macular degeneration (HTRA1) or cell death in reperfusion-ischemia (HTRA2).
First-in-class inhibitors for HTRA
Novel promising drug target for various indications
Ahp-cyclodepsipeptides constitute a novel class of HTRA inhibitors and are thus qualified to be further developed as “first-in-class” drugs for that target.
Ahp-cyclodepsipeptides represent a suitable scaffold for generating target-tailored inhibitors of serine proteases. They have developed a practical mixed solid- and solution-phase synthesis that allows the customized synthesis of Ahp-cyclodepsipeptides and thus tailored inhibitor synthesis.
Licensing
14/05/2018 00:00:00
WO2018EP62381 20180514
- international:
C07K7/06; C07K7/54
- cooperative:
C07K11/00; C12Q1/37; A61K38/00; G01N2500/04
Patent application
4907
德国
